Is Baudax Bio, Inc. (BXRXQ) a Buy, Sell, or Hold?
OTC : BXRXQ
Baudax Bio, Inc.
$0.0001 USD
$0 (0.0%)
- Volume
- 1
- Average Volume
- 3.76K
- Market Capitalization
- $4.36K
- P/E Ratio
- 0.00
- Dividend Yield
- 0.00%
- Price Target
- Year High
- $0.00
- Year Low
- $0.00
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $0.30
Company Overview
OTC
Gerri Henwood
Biotechnology
Healthcare
BXRXQ
9
US
USD
Liquidity Metrics
-0.29
0.30
0.30
0.25
0.00
Sales & Valuation
$1.27M
0.00
0.00
0.00
-83.87
Profitability
-$177.3
-$58.8M
-4633.18%
-4633.18%
1067.45%
-586.07%
P/E Metrics
0.00
0.00
0.00
Analyst Price Target & Rating
0/5
1 Analysts
%
Financial Health Scores
-17.42
1/9
-$17.71M
$20.58M
$30.82M
-$21.99M
Key Metrics (TTM)
$1.86M
1.47
-0.06
0.30
1067.45%
974.83%
-177298976.22%
-638059.19%
-108 days
Company Executives
| Name | Title |
|---|---|
| Natalie McAndrew | Consultant & Principle Accounting Officer |
| Chan Kim Yong | Chief Scientific Officer & Director |
| Geraldine A. Henwood | President, Chief Executive Officer & Director |
| Mike Choi | Vice President of Financial Planning & Analysis |
Poll Results
No votes yet today — be the first to share your view!
About Baudax Bio, Inc. (OTC:BXRXQ) Stock
Baudax Bio, Inc., a biotechnology company, develops and commercializes products for hospital and other acute care related settings. The company develops T cell receptor, that focus on immune modulating therapies for orphan diseases or complications associated with such diseases, as well as the treatment of autoimmune disorders. It also develops BX1000, an intermediate-acting neuromuscular blocking agent (NMB) that is in phase II clinical trial; BX2000, an ultra- short acting NMB, which is in phase I clinical trial, as well as a proprietary blockade reversal agent; and BX3000, a NMB reversal agent that is in preclinical studies. Baudax Bio, Inc. was incorporated in 2015 and is based in Malvern, Pennsylvania. On February 22, 2024, Baudax Bio, Inc. filed a voluntary petition for reorganizatio ... n under Chapter 11 in the U.S. Bankruptcy Court for the Eastern District of Pennsylvania.
Frequently Asked Questions
-
What is the current Baudax Bio, Inc. (BXRXQ) stock price?
-
Baudax Bio, Inc.(OTC:BXRXQ) stock price is $0.0001 in the last trading session. During the trading session, BXRXQ stock reached the peak price of $0.0001 while $0.00001 was the lowest point it dropped to. The percentage change in BXRXQ stock occurred in the recent session was 0.0% while the dollar amount for the price change in BXRXQ stock was $0.
-
BXRXQ's industry and sector of operation?
-
The OTC listed BXRXQ is part of Biotechnology industry that operates in the broader Healthcare sector.
-
Who are the executives of BXRXQ?
-
Natalie McAndrew | Consultant & Principle Accounting Officer
Chan Kim Yong | Chief Scientific Officer & Director
Geraldine A. Henwood | President, Chief Executive Officer & Director
Mike Choi | Vice President of Financial Planning & Analysis
| -
How many employees does BXRXQ have?
-
Number of BXRXQ employees currently stands at 9. BXRXQ operates from 490 Lapp Road, Malvern, PA 19355, US.
-
Link for BXRXQ official website?
-
Official Website of BXRXQ is: https://www.baudaxbio.com
-
How do I contact BXRXQ?
-
BXRXQ could be contacted at phone #484 395 2440 and can also be accessed through its website. BXRXQ operates from 490 Lapp Road, Malvern, PA 19355, US.
-
How many shares of BXRXQ are traded daily?
-
The average number of BXRXQ shares traded daily for last 3 months was 3.76K.
-
What is the market cap of BXRXQ currently?
-
The market value of BXRXQ currently stands at $4.36K with its latest stock price at $0.0001